Rosen L.S. Gordon D. Kaminski M. Howell A. Belch A. Mackey J. Apffelstaedt J. Hussein M. Coleman R.E. Reitsma D.J. Seaman J.J. Chen B.-L. Ambros Y.
(2001)
PURPOSE: Zoledronic acid, a new and more potent bisphosphonate, was compared with pamidronate, the current standard treatment for patients with osteolytic or mixed bone metastases/lesions. PATIENTS AND METHODS: A total of ...